(HealthDay News) – Generic topical prostaglandin analogs (PGAs) and treatment with laser trabeculoplasty (LTP) are both cost-effective for treatment of newly diagnosed mild open-angle glaucoma, with PGAs providing better quality of life relative to LTP, according to a study published online Feb. 13 in the Archives of Ophthalmology.
Joshua D. Stein, MD, from the University of Michigan in Ann Arbor, and colleagues used a Markov model to compare the incremental cost-effectiveness of treating newly diagnosed mild open-angle glaucoma with PGAs, LTP, or observation only.
The investigators found that, compared with no treatment, the incremental cost-effectiveness of LTP per quality-adjusted life year was $16,824, and for PGAs, it was $14,179. PGAs provided greater quality of life compared with LTP. In the case of poor patient adherence, where PGAs are 25% less effective, LTP can confer greater value.
“Generic PGAs and LTP can both be cost-effective options for managing patients with newly diagnosed mild open-angle glaucoma. Assuming optimal medication adherence, generic PGAs confer greater value compared with LTP. However, when assuming more realistic levels of medication adherence, at current prices for PGAs, LTP may be a more cost-effective alternative,” the authors write.